Logo

BASF Licenses CRISPR/Cas9 From Broad Institute for Ag-Bio, Industrial Microbe Applications

Mar 22, 2017 | staff reporter

NEW YORK (GenomeWeb) – BASF announced it has reached a non-exclusive, worldwide licensing agreement with the Broad Institute for CRISPR/Cas9 genome editing in ag-bio and industrial applications.

"We are eager to see the new ways it will augment our research and improve multiple products for agriculture as well as numerous industrial applications," Peter Eckes, president of BASF bioscience research, said in a statement.

It's the Broad's second ag-bio licensing deal for CRISPR/Cas9, following the September 2016 agreement with Monsanto.

Filed under

Business News
Gene Editing, Gene Silencing, & CRISPR
Applied Markets: Ag-Bio, Veterinary, Forensics, Food Safety, & Environmental Testing
licensing agreement
Broad Institute
CRISPR
BASF
Breaking News
The Scan

Cancer Survival Linked to Mutational Burden in Pan-Cancer Analysis

A pan-cancer paper appearing in JCO Precision Oncology suggests tumor mutation patterns provide clues for predicting cancer survival that are independent of other prognostic factors.

Australian Survey Points to Public Support for Genetic Risk Disclosure in Relatives of At-Risk Individuals

A survey in the European Journal of Human Genetics suggests most adult Australians are in favor of finding out if a relative tests positive for a medically actionable genetic variant.

Study Links Evolution of Stony Coral Skeleton to Bicarbonate Transporter Gene

A PNAS paper focuses on a skeleton-related bicarbonate transporter gene introduced to stony coral ancestors by tandem duplication.

Hormone-Based Gene Therapy to Sterilize Domestic Cat

A new paper in Nature Communication suggests that gene therapy could be a safer alternative to spaying domestic cats.